IP Library › Patent Application 17072468
Patent Application
App. No. 17/072,468

Method of Treating Insulin Resistance

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/072,468
Abstract

A method of treating hyperglycemia, diabetes, metabolic syndrome, insulin resistance (insulin insensitivity), impaired glucose tolerance, high glucose levels, pulmonary hypertension, and/or a condition arising from any of the foregoing in a patient is provided. The method comprises knocking down mARC2 or mARC1 expression in the patient, or otherwise decreasing mARC2 and mARC1 activity in the patient.

Claims (20)

1 . A method of treating diabetes, metabolic syndrome, or insulin resistance-associated pulmonary hypertension in a patient in need thereof, comprising knocking down expression of a mitochondrial amidoxime reducing component (mARC) in a patient, thereby treating diabetes, metabolic syndrome, or insulin resistance-associated pulmonary hypertension in the patient, wherein the mARC is mARC2 or mARC1.

2 . The method of claim 1 , for treating diabetes in a patient in need thereof, comprising knocking down expression of a mitochondrial amidoxime reducing component (mARC) in a patient, thereby treating diabetes in the patient, wherein the mARC is mARC2 or mARC1.

3 . The method of claim 1 , comprising treating diabetes in the patient by knocking down expression of the mARC in the patient, thereby reducing plasma insulin levels in the patient.

4 . The method of claim 1 , wherein the mARC mRNA levels are reduced in a cell of the patient.

5 . The method of claim 1 , wherein the mARC mRNA levels are reduced by administration of a RNAi agent to the patient.

6 . The method of claim 5 , wherein the RNAi specifically hybridizes to the nucleic acid of SEQ ID NO: 1 or the nucleic acid of SEQ ID NO: 2.

7 . The method of claim 5 , wherein the RNAi ranges from 21-33 bases in length and comprises or consists of a sequence GTGCTCATCTCCATCATTTAT (SEQ ID NO: 5), GATGAACTCCTAATTGGTAGT (SEQ ID NO: 6), GAACTCCTAATTGGTAGTGTA (SEQ ID NO: 7), GAGGGATTGACTGAGATCTTA (SEQ ID NO: 8), ACAACAGCAGCAACGATACAT (SEQ ID NO: 9), GATGTGCAGGACGCATGTTAC (SEQ ID NO: 10), GGACCTACTACTGCCTATCAA (SEQ ID NO: 11), GAAGAGTTATCGCCAGTGTGA (SEQ ID NO: 12), GACCCTTCAGAACGAAAGTTA (SEQ ID NO: 13), GGTGTCTCAATGCTTCAATGT (SEQ ID NO: 14), GGCTGGAAGAATATCCTAGAA (SEQ ID NO: 15), or GTGATTTCAGATAGACTACTG (SEQ ID NO: 16).

8 . The method of claim 2 , wherein the diabetes is type-2 diabetes.

9 . The method of claim 1 , for treating metabolic syndrome in a patient in need thereof, comprising knocking down expression of a mitochondrial amidoxime reducing component (mARC) in a patient, thereby treating metabolic syndrome in the patient, wherein the mARC is mARC2 or mARC1.

10 . The method of claim 9 , comprising treating metabolic syndrome in the patient by knocking down expression of the mARC in the patient, thereby reducing plasma insulin levels in the patient.

11 . The method of claim 9 , wherein the mARC mRNA levels are reduced in a cell of the patient.

12 . The method of claim 9 , wherein the mARC mRNA levels are reduced by administration of a RNAi agent to the patient.

13 . The method of claim 12 , wherein the RNAi specifically hybridizes to the nucleic acid of SEQ ID NO: 1 or the nucleic acid of SEQ ID NO: 2.

14 . The method of claim 12 , wherein the RNAi ranges from 21-33 bases in length and comprises or consists of a sequence GTGCTCATCTCCATCATTTAT (SEQ ID NO: 5), GATGAACTCCTAATTGGTAGT (SEQ ID NO: 6), GAACTCCTAATTGGTAGTGTA (SEQ ID NO: 7), GAGGGATTGACTGAGATCTTA (SEQ ID NO: 8), ACAACAGCAGCAACGATACAT (SEQ ID NO: 9), GATGTGCAGGACGCATGTTAC (SEQ ID NO: 10), GGACCTACTACTGCCTATCAA (SEQ ID NO: 11), GAAGAGTTATCGCCAGTGTGA (SEQ ID NO: 12), GACCCTTCAGAACGAAAGTTA (SEQ ID NO: 13), GGTGTCTCAATGCTTCAATGT (SEQ ID NO: 14), GGCTGGAAGAATATCCTAGAA (SEQ ID NO: 15), or GTGATTTCAGATAGACTACTG (SEQ ID NO: 16).

15 . The method of claim 1 , for treating insulin resistance-associated pulmonary hypertension in a patient in need thereof, comprising knocking down expression of a mitochondrial amidoxime reducing component (mARC) in a patient, thereby treating insulin resistance-associated pulmonary hypertension in the patient, wherein the mARC is mARC2 or mARC1.

16 . The method of claim 15 , comprising treating insulin resistance-associated pulmonary hypertension in the patient by knocking down expression of the mARC in the patient, thereby reducing plasma insulin levels in the patient.

17 . The method of claim 15 , wherein the mARC mRNA levels are reduced in a cell of the patient.

18 . The method of claim 15 , wherein the mARC mRNA levels are reduced by administration of a RNAi agent to the patient.

19 . The method of claim 18 , wherein the RNAi specifically hybridizes to the nucleic acid of SEQ ID NO: 1 or the nucleic acid of SEQ ID NO: 2.

20 . The method of claim 18 , wherein the RNAi ranges from 21-33 bases in length and comprises or consists of a sequence GTGCTCATCTCCATCATTTAT (SEQ ID NO: 5), GATGAACTCCTAATTGGTAGT (SEQ ID NO: 6), GAACTCCTAATTGGTAGTGTA (SEQ ID NO: 7), GAGGGATTGACTGAGATCTTA (SEQ ID NO: 8), ACAACAGCAGCAACGATACAT (SEQ ID NO: 9), GATGTGCAGGACGCATGTTAC (SEQ ID NO: 10), GGACCTACTACTGCCTATCAA (SEQ ID NO: 11), GAAGAGTTATCGCCAGTGTGA (SEQ ID NO: 12), GACCCTTCAGAACGAAAGTTA (SEQ ID NO: 13), GGTGTCTCAATGCTTCAATGT (SEQ ID NO: 14), GGCTGGAAGAATATCCTAGAA (SEQ ID NO: 15), or GTGATTTCAGATAGACTACTG (SEQ ID NO: 16).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2020
From: GLADWIN, MARK; SPARACINO-WATKINS, COURTNEY E.; JURCZAK, MICHAEL
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 054078/0361 →